- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Cadrenal expands CAD-1005 development to two indications | 2 | Investing.com | ||
| Mo | Cadrenal erweitert Entwicklung von CAD-1005 auf zwei Indikationen | 3 | Investing.com Deutsch | ||
| Mo | Cadrenal Therapeutics Inc.: Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor's Phase 3 Discontinuation | 240 | GlobeNewswire (Europe) | Urgent Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent need for novel upstream targets, such as 12-LOX, that are being studied to address the root causes... ► Artikel lesen | |
| 21.07. | Cadrenal sucht Partner für Portfolio an Herz-Kreislauf-Medikamenten | 2 | Investing.com Deutsch | ||
| CADRENAL THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.07. | Cadrenal Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.07. | Cadrenal Therapeutics Reports Clinical Data From Phase 2 Study Of CAD-1005 | 2 | RTTNews | ||
| 13.07. | Cadrenal stellt vielversprechende Phase-2-Daten für Thrombose-Medikament vor - Aktie dennoch unter Druck | 5 | Investing.com Deutsch | ||
| 13.07. | Cadrenal Therapeutics Inc.: Cadrenal Therapeutics' Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress | 174 | GlobeNewswire (Europe) | Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in... ► Artikel lesen | |
| 10.07. | Cadrenal Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.07. | Cadrenal Therapeutics raises $3 million in private placement | 2 | Investing.com | ||
| 01.07. | Cadrenal Therapeutics Inc.: Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules | 1 | GlobeNewswire (USA) | ||
| 29.06. | Cadrenal Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.06. | Cadrenal's HIT drug data selected for presentation at Paris congress | 2 | Investing.com | ||
| 24.06. | Cadrenal Therapeutics Inc.: Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress | 240 | GlobeNewswire (Europe) | Selection highlights the clinical value potential of Cadrenal's first-in-class 12-lipoxygenase inhibitor for Heparin-Induced Thrombocytopenia (HIT) First-ever randomized, blinded, placebo-controlled... ► Artikel lesen | |
| 18.06. | Cadrenal plans rare pediatric disease designation for tecarfarin | 1 | Investing.com | ||
| 18.06. | Cadrenal Therapeutics beantragt FDA-Sonderstatus für Tecarfarin bei seltener Kinderkrankheit | 6 | Investing.com Deutsch | ||
| 18.06. | Cadrenal Therapeutics Inc.: Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease | 1 | GlobeNewswire (USA) | ||
| 18.06. | Cadrenal Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.06. | Cadrenal Therapeutics Inc.: Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026 | 144 | GlobeNewswire (Europe) | New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussionsAdditional billion-dollar target- Cardiac Surgery-Associated... ► Artikel lesen | |
| 03.06. | Cadrenal Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,70 | +3,33 % | BioNTech SE und Emyria Limited: Wenn schlafende Biotech-Riesen erwachen und datenstarke Plattformen den Markt erobern | ||
| EVOTEC | 3,464 | +0,93 % | Übernahmekandidaten! Steyr Motors nach 20 %-Sprung! RE Royalties spannend! Und was macht Evotec? | Um 20 % ist die Aktie von Steyr Motors in der vergangenen Woche kurzzeitig explodiert. Grund waren Übernahmespekulationen durch einen Drohnen- und Robotikspezialisten aus den USA. Die Gespräche wurden... ► Artikel lesen | |
| BB BIOTECH | 55,70 | +1,27 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| AMGEN | 355,85 | +0,13 % | Ihre wichtigsten Termine: Q2-Updates von SpaceX, Bayer, Biontech, Spotify, Pfizer, Continental, Merck & Co | © Foto: Dall-EGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 05:00 Uhr, Großbritannien:... ► Artikel lesen | |
| NOVAVAX | 6,850 | -0,29 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| BIOGEN | 178,40 | -0,82 % | Biogen Inc.: Biogen Completes Acquisition of RayThera Inc. | Lead program now in Phase 1 developmentCAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately... ► Artikel lesen | |
| CLINUVEL | 5,666 | -1,05 % | Clinuvel Pharmaceuticals Limited: CLINUVEL implements strategic reorganisation to refocus on U.S. markets | MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced a strategic reorganisation of its operations and workforce... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,250 | -1,35 % | Viking Therapeutics, BioNxt Solutions, Bausch Health - Studienerfolg entfacht neue Fantasie | Die Pharmaindustrie steht vor einer neuen Wachstumsphase. Milliarden fließen in innovative Therapien, moderne Arzneimitteltechnologien und die Weiterentwicklung etablierter Medikamente. Besonders dynamisch... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,300 | -0,39 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| TEMPUS AI | 45,180 | +0,30 % | BTIG cuts Tempus AI stock price target to $70 on model update | ||
| EDITAS MEDICINE | 2,550 | +2,41 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,172 | +0,79 % | Biocryst outlines $690M-$715M 2026 total revenue guidance with operating costs at $420M-$440M | ||
| BIOMARIN PHARMACEUTICAL | 55,16 | +6,90 % | BioMarin Pharmaceutical Inc.: BioMarin Reports Second Quarter 2026 Financial and Operating Results | Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million
Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,281 | +2,18 % | Der Weg zur Klinik: Wie Finanzierung Biotech-Erfolge ermöglicht | ||
| EXELIXIS | 46,000 | -1,67 % | Exelixis outlines zanza CRC launch plans as 2026 revenue guidance midpoint is lowered by $50M |
CADRENAL THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,920 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CADRENAL THERAPEUTICS INC finden Sie auf Wallstreet Online.